Exchange: NASDAQ·Updated 04:10 PM EST
NEUP logo

NEUP Neuphoria Therapeutics Inc.

$2.28
$0.01
(0.44%)
Today
Closed $2.28
$0.00
(0.00%)
After Hours
Mkt Cap$12.28M
Vol24,224.00

About NEUP

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded in 1996 and is headquartered in Millis, MA.
65

Bullish Sentiment

How do you feel about NEUP?

13AFuse
$NEUP What seems slightly odd is how Neuphoria shareholders on this bulletin board appear to have very little interest in Scancell, the company they are merging with. Scancell have a Cancer Vaccine going in to Phase 3, with Phase 2 data points that are market leading. Yesterday $SLS announced their Phase 3 cancer vaccine trial results out. It’s a niche cancer versus the melanoma that SCLP target, so they have a much smaller target market than SCLP. Positive results tonight has seen their share price double to nearly $4BN $MRNA is the best performing stock in the S & P 500, and by some distance this year, all because of their cancer vaccine results a couple of months ago. MRNA added approx $60 bn to their mcap from thise trial resuktss. Scancell is a $5 bn+ company on good phase 3 data in my opinion, that’s 25-30x upside
4
skyrockets_Inc
$NEUP If Lynx is reading this, please contact me privately. There is a group of us building significant positions here and I'm starting to consider about voting my shares AGAINST this merger w/ Scancell. It does not seem to provide much value to existing NEUP shareholders. The CVR also appears to exclude any proceeds from BNC210. Existing shareholders are getting screwed and any potential proceeds will go to Scancell instead. They are basically stealing the company and NEUP shareholders are getting very little in return. From the looks of the merger background in the F-4 it seems like NEUP had several other options that were probably in the better interests of existing shareholders. Tell me if I'm wrong here.....
1
2
Lima2111
$NEUP Just as a follow up: I’ve reached out to Spyros via email and WhatsApp and he keeps ignoring our demand for a call. It’s super frustrating to say the least with the stock price continuing to tank. Market seems to factor in the cash risk although cash preservation has been quite good and should last beyond any realistic merger completion. At this point I’m frustrated with how management has been dealing with communication overall and seems to give zero concern about shareholders. Scancell share price not helping much either but even with their depressed price and cash this trades far below cash alone as of latest filing and below implied deal value. What are your thoughts on next steps? I don’t see a reliable exit with the thin order book and still believe there’s upside in Scancell but that’s a long term possibility
2
13AFuse
$NEUP Those thinking of voting no to the SCLP deal are ignoring some important details. • If the vote fails, NEUP must reimburse Scancell's deal costs out of its cash (No Vote Payment, s9.03(a)). What a failed vote burns (my estimates): NEUP Cash 30 Jun: $19.9M • Normal burn to YE: $1-2m • NEUP's own deal fees: $1.5-3m • Reimburse SCLP (No Vote Payment, s9.03(a)): $3-6M = Total burn: $5.5-11m Cash left: ~$9-14m = ~$1.65-2.65/share (5.41m shares) Lynx priced bids as cash + ~$0.64 premium. On that cash, a new bid = ~$2.30-3.30. Therefore the Scancell deal = ~$4.05/share at 80p, plus the CVR. Voting NO equals swapping ~$4 + CVR for a hoped-for ~$3.
3
Lima2111
$NEUP Sending an email to $NEUP CEO Spyros tomorrow on behalf of retail holders — 5 specific questions on 1. the Newbridge fairness opinion 2. the Lynx1 offers 3. BNC210 CVR removal 4. BNC210 partnership status 5. Merck collab status Already have ~200k shares behind this together with . If you want to add your name/shares to the group, DM me. The more weight behind it the better. I remember have some skin in the game here
3
Lima2111
$NEUP As shared this with me, some patient insights from Reddit: I still believe there’s music in this asset, and it’ll be monetised: of course via CVR would be best for us but even a direct sale at a decent price to NewCo will help lift up the depressing price as of now
2
skyrockets_Inc
$NEUP Anyone have any thoughts on below from F-4? So do NEUP CVR holders get proceeds from a potential BNC210 sale or will proceeds go to the combined new Scancell/NEUP co. instead? "On May 13, 2026, NEUP's initial CVR draft contemplated payments tied to the disposition of legacy assets, particularly BNC210, within two years after closing. It also included specified milestones under the Merck and CRC commercialisation agreements. By May 21, the parties had revised the CVR structure to remove the disposition of BNC210 as a distinct payment trigger and eliminate the separate milestone-amount component. The revised concept instead centered on 100% of amounts actually received under the defined Partner Agreements. The negotiations continued through July, adding or refining certain Merck-related IP-disposition provisions and the Australian R&D tax-credit claim. The final CVR is therefore not a blanket entitlement to proceeds from selling every legacy NEUP asset"
2
joe77w
$NEUP NEUP is trading at 30% discount to merger terms according my math (Giving no value to CVRs), SCANCELL trading at infimous pps, what a sell off, It Lost 2/3 of its value this year from highs of 28, right now 8.7. If deal almost certain, NEUP should be trading around 5 USD in order to reflect Merger terms plus CVRs (minimal value .65). I dont understand what happened to Bnc210, if sold NEUP could sweeten the deal terms to holders Giving a special dividend or put the Money in SCANCELL claiming Major stake in the merged co. I am not happy how deal managed, Company could have been sold or monetized for 5 USD if not more a year ago, now a year later It Is trading for 3 USD and I would not be surprised to see It at 2 sooner or later without a decent update. Lets Hope the best for every stakeholders, market bad route does not help imo.
1

Advertisement|Remove ads.